✦ LIBER ✦

Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma

✍ Scribed by David A. Amato; Howard Bruckner; DuPont Guerry; Arlene Ash; Geoffrey Falkson; Ernest C. Borden; Richard H. Creech; Edwin D. Savlov; Thomas J. Cunningham

Publisher: Springer US
Year: 1987
Tongue: English
Weight: 418 KB
Volume: 5
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00175301

No coin nor oath required. For personal study only.

✦ Synopsis

In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6o7o (3/50) for AHC, 9O7o (3/34) for DBD, and 14o70 (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.

📜 SIMILAR VOLUMES

Cisplatin. A phase II evaluation in prev

Cisplatin. A phase II evaluation in previously untreated patients with soft tissue sarcomas

✍ Peter P. Sordillo; Gordon B. Magill; Joseph Brenner; Edgar W. Cheng; Michael Dos 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB 👁 2 views

Phase II evaluation of fluorouracil and

Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinoma

✍ Richard Pazdur; Jaffer J. Ajani; James L. Abbruzzese; Robert J. Belt; Shaker R. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB 👁 1 views

Phase II study of daunorubicin in previo

Phase II study of daunorubicin in previously untreated patients with advanced colorectal carcinoma

✍ Harvey, J. ;Bonnem, E. ;Grady, K. ;Goodman, A. ;Schein, P. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Fourteen patients with advanced measurable colorectal cancer were treated with daunorubicin hydrochloride (DNR). The drug was administered at a dose of 15 mg/m2 on day 1 through 3 and 8 through 10. After a Cday rest period DNR was given in weekly injections of 15 mg/m2. There were no partial or comp

A phase 2, randomized study of SB-485232

A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma

✍ Ahmad A. Tarhini; Michael Millward; Paul Mainwaring; Richard Kefford; Ted Logan; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 1 views

Phase II study of 10-EdAM in patients wi

Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy

✍ Michael D. Green; Peter Sherman; John Zalcberg 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 310 KB

Phase II trial of irinotecan, paclitaxel

Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma

✍ Mark A. Socinski; Alan B. Sandler; Valerie K. Israel; Heidi H. Gillenwater; Lang 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract ## BACKGROUND This Phase II multicenter, open‐label, single‐arm study evaluated the efficacy and safety of a three‐drug combination of irinotecan (CPT‐11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC). ## METHODS Patients received repeated 21‐day cycle